Regeneron, Sanofi Report FDA Approval Of Kevzara (Sarilumab) For Treatment Of Patients Weighing 63 Kg Or Greater With Active Polyarticular Juvenile Idiopathic Arthritis
Portfolio Pulse from Benzinga Newsdesk
Regeneron and Sanofi have announced that the FDA has approved Kevzara (Sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis.
June 11, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron has received FDA approval for Kevzara (Sarilumab) for treating active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more. This approval could boost Regeneron's market position and revenue.
FDA approval of Kevzara for a new indication can lead to increased sales and market share for Regeneron, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi, in collaboration with Regeneron, has received FDA approval for Kevzara (Sarilumab) for treating active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more. This approval could enhance Sanofi's product portfolio and revenue.
FDA approval of Kevzara for a new indication can lead to increased sales and market share for Sanofi, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100